Nazanin Majd
University of Cincinnati
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nazanin Majd.
Molecular Cell | 2016
Kazutaka Sumita; Yu-Hua Lo; Koh Takeuchi; Miki Senda; Satoshi Kofuji; Yoshiki Ikeda; Jumpei Terakawa; Mika Sasaki; Hirofumi Yoshino; Nazanin Majd; Yuxiang Zheng; Emily Rose Kahoud; Takehiro Yokota; Brooke M. Emerling; John M. Asara; Tetsuo Ishida; Jason W. Locasale; Takiko Daikoku; Dimitrios Anastasiou; Toshiya Senda; Atsuo T. Sasaki
While cellular GTP concentration dramatically changes in response to an organisms cellular status, whether it serves as a metabolic cue for biological signaling remains elusive due to the lack of molecular identification of GTP sensors. Here we report that PI5P4Kβ, a phosphoinositide kinase that regulates PI(5)P levels, detects GTP concentration and converts them into lipid second messenger signaling. Biochemical analyses show that PI5P4Kβ preferentially utilizes GTP, rather than ATP, for PI(5)P phosphorylation, and its activity reflects changes in direct proportion to the physiological GTP concentration. Structural and biological analyses reveal that the GTP-sensing activity of PI5P4Kβ is critical for metabolic adaptation and tumorigenesis. These results demonstrate that PI5P4Kβ is the missing GTP sensor and that GTP concentration functions as a metabolic cue via PI5P4Kβ. The critical role of the GTP-sensing activity of PI5P4Kβ in cancer signifies this lipid kinase as a cancer therapeutic target.
The Journal of Cancer Research | 2014
Nazanin Majd; Kazutaka Sumita; Hirofumi Yoshino; Dillon Chen; Jumpei Terakawa; Takiko Daikoku; Satoshi Kofuji; Richard Curry; Ronald E. Warnick; Jessica Guarnaschelli; Atsuo T. Sasaki
Tumor cells adapt to their high metabolic state by increasing energy production. To this end, current efforts in molecular cancer therapeutics have been focused on signaling pathways that modulate cellular metabolism. However, targeting such signaling pathways is challenging due to heterogeneity of tumors and recurrent oncogenic mutations. A critical need remains to develop antitumor drugs that target tumor specific pathways. Here, we discuss an energy metabolic pathway that is preferentially activated in several cancers as a potential target for molecular cancer therapy. In vitro studies have revealed that many cancer cells synthesize guanosine triphosphate (GTP), via the de novo purine nucleotide synthesis pathway by upregulating the rate limiting enzyme of this pathway, inosine monophosphate dehydrogenase (IMPDH). Non-proliferating cells use an alternative purine nucleotide synthesis pathway, the salvage pathway, to synthesize GTP. These observations pose IMPDH as a potential target to suppress tumor cell growth. The IMPDH inhibitor, mycophenolate mofetil (MMF), is an FDA-approved immunosuppressive drug. Accumulating evidence shows that, in addition to its immunosuppressive effects, MMF also has antitumor effects via IMPDH inhibition in vitro and in vivo. Here, we review the literature on IMPDH as related to tumorigenesis and the use of MMF as a potential antitumor drug.
Journal of Biological Chemistry | 2014
Kazutaka Sumita; Hirofumi Yoshino; Mika Sasaki; Nazanin Majd; Emily Rose Kahoud; Hidenori Takahashi; Koh Takeuchi; Taruho Kuroda; Susan Lee; Pascale G. Charest; Kosuke Takeda; John M. Asara; Richard A. Firtel; Dimitrios Anastasiou; Atsuo T. Sasaki
Background: Targeting oncogenic K-Ras for cancer therapy has remained challenging. Results: Ubiquitination specifically occurs on the activated K-Ras orthologue in Dictyostelium via evolutionary conserved K-Ras lysines, which promotes K-Ras protein degradation. Conclusion: Our results indicate the existence of GTP-loaded K-Ras orthologue-specific degradation system in Dictyostelium. Significance: This work reveals a novel negative feedback regulation for the K-Ras isoform, which is critical for cytokinesis in Dictyostelium. Mammalian cells encode three closely related Ras proteins, H-Ras, N-Ras, and K-Ras. Oncogenic K-Ras mutations frequently occur in human cancers, which lead to dysregulated cell proliferation and genomic instability. However, mechanistic role of the Ras isoform regulation have remained largely unknown. Furthermore, the dynamics and function of negative regulation of GTP-loaded K-Ras have not been fully investigated. Here, we demonstrate RasG, the Dictyostelium orthologue of K-Ras, is targeted for degradation by polyubiquitination. Both ubiquitination and degradation of RasG were strictly associated with RasG activity. High resolution tandem mass spectrometry (LC-MS/MS) analysis indicated that RasG ubiquitination occurs at C-terminal lysines equivalent to lysines found in human K-Ras but not in H-Ras and N-Ras homologues. Substitution of these lysine residues with arginines (4KR-RasG) diminished RasG ubiquitination and increased RasG protein stability. Cells expressing 4KR-RasG failed to undergo proper cytokinesis and resulted in multinucleated cells. Ectopically expressed human K-Ras undergoes polyubiquitin-mediated degradation in Dictyostelium, whereas human H-Ras and a Dictyostelium H-Ras homologue (RasC) are refractory to ubiquitination. Our results indicate the existence of GTP-loaded K-Ras orthologue-specific degradation system in Dictyostelium, and further identification of the responsible E3-ligase may provide a novel therapeutic approach against K-Ras-mutated cancers.
Neuro-oncology | 2017
Nazanin Majd; Dawewoo Han; Mika Sasaki; Hirofumi Yoshino; Kofuji Satoshi; Rekha Chaudhary; Ronald E. Warnick; A. J. Steckl; Atsuo T. Sasaki
Neuro-oncology | 2017
Kofuji Satoshi; Akiyoshi Hirayama; Naoya Sakamoto; Kazutaka Sumita; Hirofumi Yoshino; Mikako Warren; Risa Kawaguchi; Tatsuya Ozawa; Nobuyuki Onishi; Kara Wolfe; Koichi Okumura; Annmarie Ramkissoon; Lionel M.L. Chow; Akshiv Malhotra; Jumpei Terakawa; Takiko Daikoku; Trisha Wise-Draper; Nazanin Majd; Kaori Kofuji; Mika Sasaki; Masaru Mori; Dimitrios Anastasiou; Hiroaki Wakimoto; Holger Bierhoff; Craig Horbinski; Wataru Yasui; Hideyuki Saya; Tomoyoshi Soga; Eric C. Holland; Ingrid Grummt
Journal of Clinical Oncology | 2016
Jaskirat Randhawa; Hirofumi Yoshino; Takashi Kobayashi; Satoshi Kofuji; Kara Finley; Nazanin Majd; Akshiv Malhotra; Toshinari Yamasaki; Shinsuke Shibuya; Osamu Ogawa; Koichi Okumura; Atsuo T. Sasaki
Neurology | 2014
Nazanin Majd; Kazutaka Sumita; Hirofumi Yoshino; Dillon Chen; Atsuo T. Sasaki
Neuro-oncology | 2014
Nazanin Majd; Elizabeth Neil; Ronald E. Warnick; John M. Tew; Richard Curry
Neuro-oncology | 2014
Elizabeth Neil; Nazanin Majd; John Morris; Nagla Abdel Karim; Jennifer Molano; Patricia Colapietro; Richard Curry
Neuro-oncology | 2014
Kazutaka Sumita; Mindy I. Davis; Rajan Pragani; Jumpei Terakawa; Takiko Daikoku; Nazanin Majd; Min Shen; Zhuyin Li; Xin Hu; Lewis C. Cantley; Matthew B. Boxer; Anton Simeonov; Atsuo T. Sasaki